4SC (XTRA:VSCA) - Share price, News & Analysis

VSCA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

VSCA Stock Overview

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs in Germany.

Risk Analysis

Earnings have declined by 1.7% per year over past 5 years

Does not have a meaningful market cap (€20M)

4SC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for 4SC
Historical stock prices
Current Share Price	€1.99
52 Week High	€7.90
52 Week Low	€1.88
Beta	0.76
1 Month Change	0.50%
3 Month Change	-15.14%
1 Year Change	-72.36%
3 Year Change	-86.08%
5 Year Change	-88.63%
Change since IPO	-98.20%

Recent News & Updates

Feb 13

We're Not Very Worried About 4SC's (ETR:VSCA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Aug 27

We Think 4SC (ETR:VSCA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

	VSCA	DE Biotechs	DE Market
7D	1.0%	4.3%	-0.09%
1Y	-72.4%	-31.4%	-12.9%

Return vs Industry: VSCA underperformed the German Biotechs industry which returned -31.4% over the past year.

Return vs Market: VSCA underperformed the German Market which returned -12.9% over the past year.

Price Volatility

Is VSCA's price volatile compared to industry and market?
VSCA volatility
VSCA Average Weekly Movement	5.4%
Biotechs Industry Average Movement	8.0%
Market Average Movement	6.3%
10% most volatile stocks in DE Market	10.6%
10% least volatile stocks in DE Market	3.5%

Stable Share Price: VSCA is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: VSCA's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1997	46	Jason Loveridge	https://www.4sc.com

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs in Germany. Its products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase Ib/II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. The company also out-licenses its products to pharma and biotech companies for the treatment of cancer.

4SC Fundamentals Summary

How do 4SC's earnings and revenue compare to its market cap?
VSCA fundamental statistics
Market Cap	€20.13m
Earnings (TTM)	-€10.17m
Revenue (TTM)	€14.01m

1.4x

P/S Ratio

-2.0x

P/E Ratio

Is VSCA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
VSCA income statement (TTM)
Revenue	€14.01m
Cost of Revenue	€392.00k
Gross Profit	€13.62m
Other Expenses	€23.79m
Earnings	-€10.17m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 09, 2022

Earnings per share (EPS)	-1.01
Gross Margin	97.20%
Net Profit Margin	-72.56%
Debt/Equity Ratio	0%

How did VSCA perform over the long term?

See historical performance and comparison

Valuation

Is 4SC undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

0.73x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VSCA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VSCA's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: VSCA is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: VSCA is unprofitable, so we can't compare its PE Ratio to the German market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VSCA's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: VSCA is good value based on its PB Ratio (0.7x) compared to the DE Biotechs industry average (1.5x).

Future Growth

How is 4SC forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

78.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as 4SC has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has 4SC performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-1.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VSCA is currently unprofitable.

Growing Profit Margin: VSCA is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: VSCA is unprofitable, and losses have increased over the past 5 years at a rate of 1.7% per year.

Accelerating Growth: Unable to compare VSCA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VSCA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: VSCA has a negative Return on Equity (-36.75%), as it is currently unprofitable.

Financial Health

How is 4SC's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: VSCA's short term assets (€29.5M) exceed its short term liabilities (€5.4M).

Long Term Liabilities: VSCA's short term assets (€29.5M) exceed its long term liabilities (€1.1M).

Debt to Equity History and Analysis

Debt Level: VSCA is debt free.

Reducing Debt: VSCA had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VSCA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VSCA has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 5.2% each year.

Dividend

What is 4SC current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate VSCA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VSCA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VSCA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VSCA's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VSCA has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

11.8yrs

Average board tenure

CEO

Jason Loveridge

5.67yrs

Tenure

€519,000

Compensation

Dr. Jason Loveridge, B.Sc, Ph D, FRSM, has been Corporate Advisor of Resonance Health Limited since June 30, 2017. Dr. Loveridge is a Founder of Invex.Dr. Loveridge has been Chairman of Management Board a...

CEO Compensation Analysis

Compensation vs Market: Jason's total compensation ($USD547.53K) is above average for companies of similar size in the German market ($USD404.30K).

Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.

Board Members

Experienced Board: VSCA's board of directors are seasoned and experienced ( 11.8 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/21 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31